Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence found in previous ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...

Researchers from the University of Pittsburgh School of Medicine have linked pulmonary arterial hypertension (PAH), a ...

Exercise PH — measured by the mPAP/CO slope — may predict survival in patients with normal or mildly elevated pulmonary arterial pressure.

SAN DIEGO - Gossamer Bio, Inc. (NASDAQ:GOSS), a biopharmaceutical company in the clinical stage with a market capitalization of $225 million, has shared new research findings on its drug candidate ...

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.

Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...